News
FDA approves cannabidiol for tuberous sclerosis complex
The agency approved the drug for patients 1 year of age and older.
News
Positive phase 3 top-line results for migraine prevention drug
Atogepant 10, 30, and 60 mg, were associated with a significant reduction from baseline in mean monthly migraine days compared with placebo.
News
AMA urges change after dramatic increase in illicit opioid fatalities
Illicit drugs are now the dominant reason why drug overdoses kill more than 70,000 people each year, the report says.
News
Captopril questioned for diabetes patients in COVID-19 setting
Captopril appears to be associated with a higher rate of pulmonary adverse reactions in patients with diabetes than that of other ACE inhibitors...
News
Intervention for AVM still too high risk: The latest from ARUBA
The ARUBA trial was stopped prematurely because of a much higher rate of death and stroke in the intervention group.
News
Circadian rhythm changes linked to future Parkinson’s disease risk
Circadian rhythmicity could be a promising intervention target and may open new opportunities for the prevention and management of Parkinson’s...
News
CVD risk continues to fall down to systolic BP of 90 mm HG
“From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”
News
Relapsing, progressive MS classifications should be abandoned
“The disease appears to be more of a continuum of disability progression, which is sometimes also accompanied by relapses.”
News
COVID-19 neurologic effects: Does the virus directly attack the brain?
There are neurologic sequelae of COVID-19. “We need to be alert to these, and to try to understand the potential long-term consequences.”
News
No benefit of three commonly used medications for MS fatigue
These findings will hopefully encourage doctors to “think twice before prescribing these medications that could be harmful and have no clear...
News
More from REDUCE-IT: Icosapent ethyl cuts revascularization by a third
The high-strength eicosapentaenoic acid product reduced revascularizations by one-third in patients at increased cardiovascular risk and...
News
ACE inhibitors and severe COVID-19: Protective in older patients?
A randomized trial is planned after a study showed that fewer older hypertensive patients taking ACE inhibitors were hospitalized with COVID-19....
News
Statins and ICH: new meta-analysis
The risk for cerebral ischemia was significantly lower in those who received statins compared with who did not.
News
New angiotensin studies in COVID-19 give more reassurance
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
News
Diastolic dysfunction is a common risk factor for cognitive decline
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic...